Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of GSK5926371 in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
jRCT2031260191Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of GSK5926371 in mature B-cell lymphoma, sponsored by GSK. Primary endpoints: Incidence of dose-limiting toxicities (DLTs) and Incidence and severity of adverse events and serious adverse events. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
GSK5926371
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on jRCT2031260191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260191.